Saxena, in his note, also said that these drugs procured by spending huge budgetary resources are a grave threat to public health and safety and have the potential of endangering lives of people.
Extraordinary demand for Novo Nordisk’s Ozempic and other drugs used for weight-loss is fueling a global surge in counterfeit versions, according to Reuters interviews with law enforcement, anti-counterfeiting and public health officials. The U.S.-based Pharmaceutical Security Institute (PSI), an industry-backed organization that counts drugmakers Novo Nordisk and Eli Lilly as members, said it is working with agencies, including Europol, Interpol and U.S. Homeland Security, as well as companies that help identify counterfeit products such as Israel’s BrandShield.